Osiris Therapeutics, a stem cell therapeutic company developing treatments for the inflammatory, orthopedic and cardiovascular areas, announced the terms for its IPO on Monday. The Baltimore based company plans to offer 3.5 millions shares at a range of $11-$13 with a proposed market cap of $333 million. Jefferies & Company, Lazard Capital Markets and Leerink Swann & Company are managing the deal. Timing has yet to be announced.
